cupric chloride has been researched along with imatinib mesylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Tamimi, J; Alhazza, IM; Aman, S; Ebaid, H; Hassan, I; Khan, AA; Qamar, W; Rady, AM | 1 |
1 other study(ies) available for cupric chloride and imatinib mesylate
| Article | Year |
|---|---|
Restrained management of copper level enhances the antineoplastic activity of imatinib in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemotherapy, Adjuvant; Copper; Disulfiram; Drug Synergism; Imatinib Mesylate; Metabolism; Neoplasms, Experimental; Rats; Treatment Outcome | 2018 |